Publicacións en colaboración con investigadores/as de Hospital Virgen de la Concha (47)

2024

  1. Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 10, pp. 1325-1338

  2. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612

  3. Patients who suffer a first atherosclerotic cardiovascular event while taking statins are often far off of lipid targets

    Nutrition, Metabolism and Cardiovascular Diseases, Vol. 34, Núm. 1, pp. 90-97

  4. Remodeling p38 signaling in muscle controls locomotor activity via IL-15

    Science advances, Vol. 10, Núm. 33, pp. eadn5993

2023

  1. ALERGODATA: Sentinel Registry of Health Outcomes in Allergic Patients Treated With Biological Therapies at Specialized Allergology Clinics in Spain

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 6, pp. 479-482

  2. Coeliac Disease Case–Control Study: Has the Time Come to Explore beyond Patients at Risk?

    Nutrients, Vol. 15, Núm. 5

  3. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

    American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247

2022

  1. Correlation of Anti-Tissue Transglutaminase Antibodies With the Mucosal Changes and IgA Status of Children With Celiac Disease

    Journal of pediatric gastroenterology and nutrition, Vol. 75, Núm. 6, pp. 743-748

  2. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  3. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

  4. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Body mass index and disease activity in chronic inflammatory rheumatic diseases: Results of the cardiovascular in rheumatology (CARMA) project

    Journal of Clinical Medicine, Vol. 10, Núm. 3, pp. 1-10

  2. Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study

    Therapeutic Advances in Gastroenterology, Vol. 14

2020

  1. Association of apolipoprotein B/apolipoprotein A1 ratio and cardiovascular events in rheumatoid arthritis: results of the CARMA study

    Clinical and experimental rheumatology, Vol. 38, Núm. 4, pp. 662-669

  2. Predictors of response to exclusive enteral nutrition in newly diagnosed crohn’s disease in children: PRESENCE Study from SEGHNP

    Nutrients, Vol. 12, Núm. 4

2019

  1. Incidence of first cardiovascular event in Spanish patients with inflammatory rheumatic diseases: prospective data from the CARMA project

    Clinical and experimental rheumatology, Vol. 37, Núm. 5, pp. 731-739

2017

  1. Eficacia, eficiencia y efectividad en el tratamiento multidimensional de la esquizofrenia: proyecto Rethinking

    Revista de Psiquiatria y Salud Mental, Vol. 10, Núm. 1, pp. 4-20

  2. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project

    Journal of Clinical Lipidology, Vol. 11, Núm. 3, pp. 749-756.e3

2016

  1. Cardiac Arrhythmias and Pacing 2015: A Selection of Topical Issues

    Revista Espanola de Cardiologia, Vol. 69, Núm. 2, pp. 167-175

  2. Cut-offs and response criteria for the Hospital Universitario la Princesa Index (HUPI) and their comparison to widely-used indices of disease activity in rheumatoid arthritis

    PLoS ONE, Vol. 11, Núm. 9